Asco-GU – confirmatory Padcev trial throws a curveball
Subgroup analysis of a confirmatory US study in bladder cancer suggests no benefit in female patients.
World Lung 2020 – Yervoy’s front-line impotence laid bare
Full data show just how big a bust Keynote-598 is, though Bristol is unlikely to abandon hope.
Pandemic mutations prompt antibody collaborations
A trial testing a combination of Lilly and Vir antibodies is the latest attempt by developers to stay ahead of the virus that causes Covid-19.
Vir becomes a biotech bubble poster child
The company surges 74% though its hints of clinical activity concern just six hep B patients and could include those on placebo.
Lilly’s Covid-19 combo catches fire
With no deaths in the treatment arm, Blaze-1 could allow emergency authorisation of the doublet antibody therapy.
A second prophylaxis win for Covid-19 antibodies
Like Lilly, Regeneron reckons its antibodies can be used to prevent Covid-19 infection. Now comes the hard part.
Merck KGaA’s dual immuno-oncology weapon misfires
Bintrafusp alfa’s most important study, head to head against Keytruda in front-line lung cancer, is scrapped.
